Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of RC278 for advanced unresectable or metastatic solid tumors
CTR20252947Phase 2Active
- Sponsor
- RemeGen
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RC278 in Nonhematologic neoplasms, sponsored by RemeGen. Started Aug 2025; status: active.
02
Drugs
RC278
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252947.